作者
Bianca Rivera-Peña, Samarpana Chakraborty, Yang Shi, Hui Zhang, Rongbao Zhao, Gaurav Choudhary, Shanisha Gordon-Mitchell, Kith Pradhan, Bowen Fu, Isidora Tosic, Carolina Schinke, Asya Varshavsky, Jonathan Feld, Mendel Goldfinger, Milagros Carbajal, Nandini Ramachandra, Marina Konopleva, David Frank, Yogen Saunthararajah, Amit Verma, Aditi Shastri
发表日期
2023/9/1
期刊
Clinical Lymphoma Myeloma and Leukemia
卷号
23
页码范围
S355
出版商
Elsevier
简介
Context
Existing therapies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have ineffectively targeted leukemic stem cells (LSCs). Targeting and eliminating LSCs could be a possible approach to curing MDS.
Introduction
MDS and AML LSCs demonstrate overexpression of STAT3, which is predictive of an adverse prognosis. An initial drug screening identified pyrimethamine (PYR), an FDA-approved anti-parasitic drug, as a potential STAT3 transcriptional modulator.
Objective
Our study evaluates the efficacy of PYR as a treatment for MDS and AML. Furthermore, we assess PYR efficacy in a hypomethylating agent (HMA) and venetoclax (Ven)-resistant model.
Methods
MDS and AML cell lines including HMA-resistant THP1 AML and Ven-resistant MOLM13 AML cell lines were treated with multiple PYR concentrations, followed by cell viability and FACS apoptosis analysis. Primary MDS patient …
学术搜索中的文章
B Rivera-Peña, S Chakraborty, Y Shi, H Zhang, R Zhao… - Clinical Lymphoma Myeloma and Leukemia, 2023